Phibro Animal Health (PAHC) major holder adopts 10b5-1 sale plan
BFI Co., LLC and Jack C. Bendheim, major holders in Phibro Animal Health (PAHC), have filed an amended Schedule 13D disclosing a new Rule 10b5-1 sales plan. This plan authorizes Goldman Sachs to sell up to 750,000 shares of Class A Common Stock by March 17, 2027, with the first trading date on September 16, 2026. BFI currently beneficially owns 48.2% of PAHC's Class A Common Stock on an as-converted basis, and would still retain a substantial stake even if all shares under the plan are sold.
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the Stifel Jaws & Paws Conference. Key executives, including Daniel Bendheim, Larry Miller, and Glenn David, will address financial analysts and investors on May 27, 2026, at 9:45 AM ET in New York. A live audio presentation and replay will be available on the company's Investor Relations website.
Barclays PLC holds 263,695 shares in Phibro (NASDAQ: PAHC)
Barclays PLC has filed an amended Schedule 13G/A, indicating beneficial ownership of 263,695 shares of Phibro Animal Health Corp-A common stock, which represents 1.27% of the class. The filing specifies that Barclays holds sole voting and dispositive power over these shares. This amendment, signed by a Barclays director on May 14, 2026, provides transparency on institutional holdings without implying control over the issuer.
Phibro Animal Health (PAHC) Margin Reset To 6.3% Tests Bullish Expansion Narrative
Phibro Animal Health (PAHC) recently reported Q3 2026 results with revenue of US$383.5 million and EPS of US$0.59. The company's trailing 12-month net profit margin is 6.3%, up from 2.7% previously, but quarterly net income has been stable between US$24.0 million and US$27.5 million. While earnings growth significantly outpaces revenue growth, the stock's P/E ratio is higher than industry averages, creating a tension for investors despite a discount to its DCF fair value.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on June 24, 2026, to shareholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global animal health and nutrition company providing solutions for farm and companion animals.
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Phibro Animal Health Corporation announced its participation in the Bank of America Securities Health Care Conference. Key executives, including Daniel Bendheim, Larry Miller, and Glenn David, will address financial analysts and investors on May 13, 2026, at 1:40 PM ET. A live audio presentation and replay will be available on the company's Investor Relations Website.
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares
Phibro Animal Health CEO Jack Bendheim, along with BFI Co., LLC, sold Class A Common Stock worth approximately $1.02 million between May 5 and May 7, 2026, under a Rule 10b5-1 trading plan. These sales involved 18,608 shares at prices ranging from $47.5908 to $58.1257, occurring despite the company's stock currently trading lower than the transaction prices but after a strong annual return. The insider sales follow Phibro's positive third-quarter fiscal 2026 results which surpassed Wall Street expectations for EPS and revenue.
CEO-linked BFI Co. (PAHC) sells 18,608 Phibro shares under plan
BFI Co., LLC, an entity linked to Phibro Animal Health's CEO Jack Bendheim, sold 18,608 shares of Class A Common Stock between May 5-7, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in open-market transactions at weighted average prices ranging from approximately $47 to $58 per share. Following these sales, BFI Co., LLC indirectly holds 56,152 shares, while Jack Bendheim directly holds 16,840 shares, though he disclaims beneficial ownership of BFI's holdings beyond his pecuniary interest.
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares
Phibro Animal Health CEO Jack Bendheim, along with BFI Co., LLC, sold approximately $1.02 million worth of Class A Common Stock in PAHC between May 5 and May 7, 2026, under a Rule 10b5-1 trading plan. The shares were sold at prices ranging from $47.5908 to $58.1257. These transactions occurred amidst stock volatility, despite the company's strong recent fiscal 2026 Q3 results which surpassed analyst expectations.
Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
Phibro Animal Health Corporation has launched its Sustainable Solutions Platform (SSP), a companywide initiative to help animal protein, dairy, and petfood producers reduce greenhouse gas emissions. As part of this, Phibro introduced Verratain™ Verified Sustainability Solutions, starting with a partnership with VAXA Technologies to offer low-carbon microalgae feed ingredients like Verratain™ Spirulina and Verratain™ Omega Oil, which target Scope 3 emissions in animal feed supply chains. Peter Bunce has been appointed Head of Sustainable Solutions to lead this platform, aiming to provide scalable and practical solutions for sustainability goals.
Phibro Animal Health declares $0.12 quarterly dividend payable June 24
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is payable on June 24, 2026, to shareholders of record as of June 3, 2026. The declaration was announced on May 5, 2026, and details were filed as Exhibit 99.1 to the company's Form 8-K.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is payable on June 24, 2026, to stockholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
[8-K] PHIBRO ANIMAL HEALTH CORP Reports Material Event
Phibro Animal Health Corporation announced an 8-K material event, declaring a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on June 24, 2026, to stockholders recorded by June 3, 2026. This filing, deemed a moderate impact with neutral sentiment, voluntarily discloses an important event for shareholders.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq:PAHC) announced its Board of Directors has declared a quarterly cash dividend of $0.12 per share. This dividend applies to both Class A and Class B common stock and is payable on June 24, 2026, to stockholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on June 24, 2026, to stockholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company dedicated to providing solutions for animal health.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Phibro Animal Health Corporation (Nasdaq: PAHC) announced it will release its third-quarter financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and webcast on Thursday, May 7, 2026, at 9:00 AM Eastern Time to discuss the results. Interested parties can access the event via their investor relations website or by phone.
CEO-associated BFI Co. trims Phibro (PAHC) stake under 10b5-1 plan
BFI Co., LLC, an entity linked to Phibro Animal Health Corp's President and CEO Jack Bendheim, sold 21,120 shares of Class A Common Stock between April 28-30, 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred at weighted average prices ranging from $52.65 to $56.69 per share. Following these transactions, BFI's indirect holdings are 74,760 shares, and Jack Bendheim directly holds 16,840 shares.
Phibro Animal Health CEO Bendheim-linked entity sells $1.1m stock
An entity linked to Phibro Animal Health Corp. CEO Jack Bendheim, BFI Co., LLC, sold approximately $1.14 million worth of Class A Common Stock between April 28 and April 30 under a pre-arranged trading plan. This sale occurred while PAHC shares had seen significant gains over the past year and year-to-date, and InvestingPro analysis suggests the stock is currently overvalued. Separately, Phibro Animal Health reported strong fiscal Q2 2026 results, surpassing analyst expectations for both EPS and revenue.
Phibro Animal Health CEO Bendheim-linked entity sells $1.1m stock
An entity linked to Phibro Animal Health Corp. (NASDAQ:PAHC) President and CEO Jack Bendheim sold approximately $1.14 million worth of Class A Common Stock between April 28 and April 30 under a pre-arranged trading plan. This sale occurred while PAHC shares have seen significant gains, and InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong fiscal Q2 2026 results, surpassing analyst expectations for both EPS and revenue.
Controlling holder of Phibro Animal Health (PAHC) reports 48.3% stake
BFI Co., LLC and Jack C. Bendheim have filed an Amendment No. 24 to Schedule 13D, reporting their updated ownership of Phibro Animal Health Corporation's Class A Common Stock. They beneficially own 19,591,914 shares, equating to 48.3% of the Class A Common Stock on an as-converted basis, which includes 95,880 Class A shares and 19,496,034 Class B shares. The filing also notes market disposals of Class A shares within the past 60 days.
Phibro Animal Health CEO Bendheim sells $1.16m in PAHC stock
Phibro Animal Health Corp. CEO Jack Bendheim, through BFI Co., LLC, sold 21,120 shares of Class A Common Stock for approximately $1.16 million between April 21 and April 23, 2026, pursuant to a Rule 10b5-1 trading plan. These sales occurred after a 222% surge in PAHC shares over the past year, with InvestingPro analysis suggesting the stock is overvalued. Despite these insider sales, the company recently reported strong fiscal Q2 2026 results, surpassing analyst expectations for both EPS and revenue.
BFI Co., LLC linked to PAHC (PAHC) sells 21,120 Class A shares
BFI Co., LLC, an entity associated with Phibro Animal Health's President and CEO Jack Bendheim, sold 21,120 Class A Common Stock shares in open-market transactions. The sales, executed under a Rule 10b5-1 trading plan, occurred at weighted average prices between $54 and $56 per share. Following these transactions, BFI Co., LLC holds 95,880 Class A shares, and Jack Bendheim directly holds 16,840 Class A shares.
Phibro Animal Health CEO Bendheim sells $1.16m in PAHC stock
Jack Bendheim, CEO of Phibro Animal Health Corp. (NASDAQ:PAHC), and BFI Co., LLC, sold 21,120 shares of Class A Common Stock worth approximately $1.16 million between April 21 and April 23, 2026. The sales were conducted via a Rule 10b5-1 trading plan. This comes as PAHC shares have surged 222% over the past year, though an InvestingPro analysis suggests the stock is currently overvalued.
Phibro Animal Health (PAHC) director sells $1.2m in shares By Investing.com
A director and a ten percent owner of Phibro Animal Health (PAHC) sold over $1.2 million worth of shares between April 14 and April 16, 2026. This comes after the stock achieved a 216% gain over the past year, trading near its 52-week high, although InvestingPro analysis suggests it may be overvalued. The company recently reported strong fiscal Q2 2026 results, surpassing analyst expectations for both earnings and revenue.
Phibro Animal Health (PAHC) director sells $1.2m in shares
Jack Bendheim, a director and ten percent owner of Phibro Animal Health Corp (NYSE:PAHC) through BFI Co., LLC, sold shares totaling over $1.2 million between April 14 and April 16, 2026. The sales occurred while the stock was trading near its 52-week high after a significant 216% gain in the past year, with InvestingPro analysis suggesting the stock may be overvalued. Concurrently, Phibro Animal Health reported strong fiscal Q2 2026 results, surpassing analyst expectations for both EPS and revenue.
Pre-planned stock sales by Phibro (PAHC) CEO-linked entity
Phibro Animal Health Corp's CEO-linked entity, BFI Co., LLC, converted 100,000 shares of Class B Common Stock to Class A and subsequently sold 21,120 Class A shares between April 14 and April 16. These open-market transactions, executed under a Rule 10b5-1 trading plan adopted in December 2025, involved shares sold at weighted average prices ranging from approximately $53.80 to $59.83. Following these sales, BFI Co., LLC indirectly holds 117,000 Class A shares, and CEO Jack Bendheim directly holds an additional 16,840 Class A shares.
Phibro Animal Health (PAHC) director sells $1.2m in shares
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a ten percent owner, sold shares worth over $1.2 million between April 14 and April 16, 2026. The sales occurred while the stock was trading near its 52-week high after a significant 216% gain over the past year. This comes after the company reported strong fiscal Q2 2026 results, exceeding analyst expectations for both earnings and revenue.
Phibro Animal Health : PAHC
This article provides key financial data for Phibro Animal Health Corp (PAHC), including its stock price, asset type, exchange, and country of origin. It also gives a brief company description, highlighting Phibro's role as a global leader in animal health and mineral nutrition. The content also refers to a related article discussing Zoetis and the pet economy.
Board member Joyce Lee to leave Phibro Animal Health (NASDAQ: PAHC)
Phibro Animal Health Corporation announced that Class II Director Joyce J. Lee will resign from its Board of Directors, effective April 15, 2026. Ms. Lee informed the company of her decision on April 13, 2026, and her resignation is not attributed to any disagreements regarding company operations, policies, or practices. This information was disclosed in an 8-K filing, indicating a standard board transition.
Is It Too Late To Consider Phibro Animal Health (PAHC) After Its 235% One-Year Surge?
Phibro Animal Health (PAHC) has seen a 235% surge over the past year, prompting an analysis of its current valuation. A Discounted Cash Flow (DCF) model suggests the stock is undervalued by 51.4%, while its P/E ratio of 25.48x indicates it is overvalued compared to industry averages and Simply Wall St's "Fair Ratio" of 17.36x. The article also presents two narrative-based valuations, ranging from US$48.50 to US$58.00, to help investors gauge different assumptions against the current share price.
FMR LLC reports 2.17M shares in PHIBRO Animal Health (PAHC) — 10.5% stake
FMR LLC has reported a 10.5% beneficial ownership stake in PHIBRO Animal Health (PAHC), totaling 2,173,126.20 shares as of March 31, 2026. The Schedule 13G filing indicates FMR LLC holds sole voting power over 2,171,187 shares and sole dispositive power over all 2,173,126.20 shares, characterizing this as a passive investment. The filing also notes that some shares are held on behalf of other persons, with details potentially available in Exhibit 99, which mentions a 13d-1(k)(1) agreement.
Is Strong Q2 Results And Portfolio Shift Altering The Investment Case For Phibro Animal Health (PAHC)?
Phibro Animal Health reported strong fiscal Q2 2026 results, exceeding revenue and earnings expectations, and demonstrating improved profitability. The company's integration of Zoetis' medicated feed additive business and an expanding vaccines franchise are shifting its product mix towards higher-value items and broader international reach, potentially reshaping its investment narrative due to accelerating earnings and margin trends. While the outlook is positive, with revenue projected to reach $1.5 billion and earnings $119.1 million by 2028, investor caution is advised regarding its fair value and potential overreliance on medicated feed additives.
Insider Sale Tests Market View Of Phibro’s Growth And Valuation
BFI Co., LLC, an entity controlled by Phibro Animal Health’s CEO, recently executed a major insider share sale. This transaction follows strong operating results and expansion in the company's vaccine portfolio and international business. The article highlights that while analysts see the stock trading above target, Simply Wall St estimates it's significantly undervalued, raising questions about management's perception of current pricing.
BFI Co. sells $757k in Phibro Animal Health (PAHC) stock
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 14,080 shares of Class A Common Stock worth approximately $756,833. These sales occurred on March 30 and March 31, 2026, at prices between $53.5415 and $54.3533, following a 10b5-1 trading plan. Despite InvestingPro’s analysis suggesting PAHC is overvalued, the company recently reported strong fiscal Q2 2026 results, surpassing earnings and revenue forecasts.
Bendheim-linked BFI Co. LLC (PAHC) sells 14,080 shares under 10b5-1
BFI Co. LLC, an entity linked to Phibro Animal Health's President and CEO Jack Bendheim, sold 14,080 shares of Class A Common Stock (PAHC) on March 30 and March 31, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, involved weighted average prices between $53.54 and $54.35 per share. Following these transactions, BFI Co. LLC indirectly holds 38,120 shares and Bendheim directly holds 16,840 shares, indicating a continued significant equity stake despite the sales.
Phibro Animal Health (PAHC) insider entity BFI Co. sells 21,120 shares
BFI Co., an entity linked to Phibro Animal Health (PAHC) President and CEO Jack Bendheim, sold 21,120 shares of Class A Common Stock between March 24–26, 2026. The sales were executed under a pre-scheduled Rule 10b5-1 trading plan at weighted average prices ranging from approximately $52.8772 to $57.1702 per share. Following these transactions, BFI Co. holds 52,200 Class A shares, and Jack Bendheim directly holds 16,840 shares.
Is Phibro Animal Health’s (PAHC) Efficiency Surge Quietly Rewriting Its Competitive Position in Animal Health?
Phibro Animal Health (PAHC) has demonstrated significant annual revenue growth of 21.7% and improved operating efficiency, which suggests it is gaining market share and enhancing profitability. The company's recent guidance for FY2026 projects net sales of US$1.45 billion to US$1.50 billion and net income of US$85 million to US$95 million, driven by better execution and integrated acquisitions. Despite these positive trends, the company's strong reliance on medicated feed additives may expose it to future regulatory or competitive pressures, which could impact the sustainability of its gains.
BFI Co sells Phibro Animal Health (PAHC) stock worth $1.19 million
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (PAHC), sold 19,980 shares of Class A Common Stock for approximately $1.19 million between March 17 and March 19, 2026. The sales were conducted under a Rule 10b5-1 trading plan. Despite the sales, Phibro Animal Health reported strong fiscal Q2 2026 results, surpassing market expectations for both earnings per share and revenue.
BFI Co sells Phibro Animal Health (PAHC) stock worth $1.19 million By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold approximately $1.19 million worth of Class A Common Stock between March 17 and March 19, 2026, as part of a Rule 10b5-1 trading plan. Despite these sales near its 52-week high, Phibro Animal Health recently reported strong fiscal Q2 2026 results, surpassing revenue and EPS expectations. However, InvestingPro analysis suggests the stock might be overvalued with a P/E ratio of 23.42.
Phibro Animal Health (PAHC) CEO-linked BFI Co. sells 22,880 shares in Rule 10b5-1 trades
An entity linked to Phibro Animal Health's President and CEO, Jack Bendheim, BFI Co., LLC, sold 22,880 shares of Class A Common Stock between March 17 and 19, 2026. These sales, conducted under a Rule 10b5-1 trading plan, occurred at weighted average prices ranging from $51.6590 to $53.6436 per share. Following these transactions, BFI Co., LLC indirectly held 73,320 shares, while Jack Bendheim directly held 16,840 shares.
Phibro Insider Moves Shift Class Structure As Stock Trades Near Highs
Phibro Animal Health Corporation is experiencing shifts in its class structure as an insider, Jack Bendheim, sold Class A shares under a pre-arranged plan, and BFI Co., LLC converted Class B shares to Class A. These moves affect insider holdings, voting rights, and the mix of share classes, occurring as the stock trades near 52-week highs following strong fiscal Q2 2026 results. The article discusses potential implications for governance, liquidity, and investor sentiment, noting that while some see these as ordinary portfolio adjustments, they also signal a lean towards more institutional ownership and a slight reduction in super-voting stock power.
BFI Co sells Phibro Animal Health (PAHC) stock worth $1.19 million
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 19,980 shares of Class A Common Stock for approximately $1.19 million between March 17 and March 19, 2026. The sales were executed under a Rule 10b5-1 trading plan, with prices ranging from $51.659 to $53.6436. Despite the stock's significant gain over the past year, InvestingPro analysis suggests it may be overvalued, though the company recently reported strong fiscal Q2 2026 results.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares By Investing.com
Phibro Animal Health (PAHC) director Jack Bendheim indirectly sold 5,280 Class A Common Stock shares for $258,244 on March 13, 2026, under a pre-arranged trading plan. Despite the sales, the stock has seen a significant 137% gain over the past year and recently reported strong fiscal Q2 2026 results, surpassing earnings and revenue expectations. InvestingPro analysis suggests the stock is currently overvalued.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares
Jack Bendheim, a director and CEO of Phibro Animal Health Corp (NASDAQ:PAHC), indirectly sold 5,280 shares of Class A Common Stock for $258,244 on March 13, 2026, under a pre-arranged trading plan. Despite sales, the stock has seen a 137% gain over the past year and recently reported strong fiscal Q2 2026 results, exceeding EPS and revenue expectations. InvestingPro analysis indicates PAHC is currently trading above its Fair Value.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares
Phibro Animal Health director Jack Bendheim indirectly sold 5,280 shares of Class A Common Stock for over $258,000 on March 13, 2026, through a pre-arranged trading plan. This transaction followed a conversion of Class B to Class A shares, leaving BFI Co., LLC with 96,200 Class A shares and Bendheim directly holding 16,840. The company recently reported strong fiscal Q2 2026 results, with earnings and revenue exceeding expectations, and its stock has seen a 137% gain over the past year.
BFI Co. tied to Phibro Animal Health (PAHC) converts and sells shares
BFI Co., LLC, an entity associated with Phibro Animal Health's President and CEO Jack Bendheim, converted 100,000 Class B shares into Class A shares and subsequently sold 5,280 Class A shares at a weighted average price of $48.91. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, BFI Co. and Jack Bendheim retain significant holdings in the company's Class A and Class B common stock.
A Look At Phibro Animal Health (PAHC) Valuation After A Strong 1 Year Total Return
Phibro Animal Health (PAHC) has seen a 135.9% total return over the past year, with revenues of US$1.46 billion and net income of US$92.09 million. While a popular narrative suggests the company is slightly overvalued at $48.50 due to non-repeatable growth drivers, a discounted cash flow model suggests it is significantly undervalued at $119.16. Investors are faced with conflicting valuation views, prompting a closer look at the company's future cash generation and growth prospects.
Multiple resale transactions by affiliate reported for Phibro Animal Health (PAHC)
Phibro Animal Health Corporation (PAHC) filed a Form 144, indicating proposed resale transactions of Class A Common Stock by its affiliate, BFI Co. LLC. The filing details multiple brokered sales from January to February 2026, including large single-day transactions. This routine disclosure provides transaction dates, share counts, and gross proceeds for the sales, but does not specify total registered shares or recipients of the proceeds.
A Look At Phibro Animal Health (PAHC) Valuation After Strong Q2 Beat And Higher Revenue Guidance
Phibro Animal Health (PAHC) significantly beat Q2 earnings and revenue expectations, leading to raised full-year revenue guidance. Despite strong recent share price performance and high returns, some analysts view the stock as overvalued at $54.54 against a fair value estimate of $48.50, attributing recent growth partly to non-repeatable synergies. However, a discounted cash flow model suggests the stock might be undervalued, trading 54.2% below an estimated $119.16, indicating divided sentiment on its true valuation.
Phibro Animal Health (PAHC) director sells $1.1 million in stock
A director and 10% owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold $1.1 million worth of Class A Common Stock between February 24 and February 26, 2026. The sales were executed via a pre-arranged Rule 10b5-1 trading plan. This comes as the stock trades near its 52-week high, and an InvestingPro analysis suggests it is overvalued.
